CHRS logo

CHRS
Coherus Biosciences Inc

5,117
Mkt Cap
$259.31M
Volume
537,249.00
52W High
$2.62
52W Low
$0.71
PE Ratio
-1.19
CHRS Fundamentals
Price
$1.73
Prev Close
$1.74
Open
$1.70
50D MA
$1.83
Beta
1.84
Avg. Volume
1.48M
EPS (Annual)
-$1.45
P/B
3.44
Rev/Employee
$286,884.35
$48.58
Loading...
Loading...
News
all
press releases
Coherus Oncology (NASDAQ:CHRS) Stock Price Passes Above 200 Day Moving Average - Should You Sell?
Coherus Oncology (NASDAQ:CHRS) Share Price Crosses Above 200 Day Moving Average - Time to Sell...
MarketBeat·3d ago
News Placeholder
More News
News Placeholder
Coherus Oncology (CHRS) Upgraded to Buy: Here's What You Should Know
Coherus Oncology (CHRS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks·10d ago
News Placeholder
Coherus Oncology (NASDAQ:CHRS) Shares Pass Above Two Hundred Day Moving Average - Here's What Happened
Coherus Oncology (NASDAQ:CHRS) Share Price Crosses Above Two Hundred Day Moving Average - What's Next...
MarketBeat·12d ago
News Placeholder
Is Biodesix (BDSX) Stock Outpacing Its Medical Peers This Year?
Here is how Biodesix, Inc. (BDSX) and Coherus Oncology (CHRS) have performed compared to their sector so far this year.
Zacks·16d ago
News Placeholder
Coherus Oncology Pivots to Immuno-Oncology, Touts LOQTORZI Growth and New Pipeline at Citizens Conf.
Coherus Oncology (NASDAQ:CHRS) used its presentation at the Citizens Life Sciences Conference to outline its transition into what CEO Denny Lanfear described as an innovative oncology company focused...
MarketBeat·22d ago
News Placeholder
Coherus Oncology (NASDAQ:CHRS) Upgraded at Wall Street Zen
Wall Street Zen raised Coherus Oncology from a "sell" rating to a "hold" rating in a research note on Saturday...
MarketBeat·22d ago
News Placeholder
Coherus Oncology Q4 Earnings Call Highlights
Coherus Oncology (NASDAQ:CHRS) outlined progress on its transition to an innovative oncology company during its fourth-quarter and full-year 2025 earnings call, highlighting a growing commercial base...
MarketBeat·26d ago
News Placeholder
Coherus Oncology (CHRS) Reports Q4 Loss, Misses Revenue Estimates
Coherus Oncology (CHRS) delivered earnings and revenue surprises of -9.68% and -2.86%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·26d ago
News Placeholder
Coherus Oncology (NASDAQ:CHRS) Announces Quarterly Earnings Results, Misses Estimates By $0.03 EPS
Coherus Oncology (NASDAQ:CHRS - Get Free Report) issued its quarterly earnings data on Monday. The biotechnology company reported ($0.34) EPS for the quarter, missing the consensus estimate of...
MarketBeat·26d ago
News Placeholder
Coherus Oncology (CHRS) Projected to Post Quarterly Earnings on Monday
Coherus Oncology (NASDAQ:CHRS) will be releasing its Q4 2025 earnings before the market opens on Monday, March 9. (View Earnings Report at...
MarketBeat·1mo ago
<
1
2
...
>

Latest CHRS News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.